Inflammatory Bowel Disease: Diagnosis and TreatmentGary L. Gitnick A clinical reference on the medical and surgical management of inflammatory bowel disease (IBD) in all age groups. Edited by a well known authority in the field and written by a group of 59 contributors from around the world, Inflammatory Bowel Disease is a major reference on this topic. Gastroenterologists, surgeons, internists, and family practitioners should be interested in this volume of the latest information on treatment and diagnosis as well as on the major new areas of research in the field. |
From inside the book
Results 1-3 of 77
Page 40
... therapeutic approaches using specific tachykinin antagonists that may contribute to suppression of the inflammatory response . EXPERIMENTAL MODELS Since the etiology of inflammatory bowel disease is unknown , it is not surpris- ing that ...
... therapeutic approaches using specific tachykinin antagonists that may contribute to suppression of the inflammatory response . EXPERIMENTAL MODELS Since the etiology of inflammatory bowel disease is unknown , it is not surpris- ing that ...
Page 276
... therapeutic moiety is 5 - ASA . Sulfasalazine is a useful drug in the treatment of mild to moderate attacks of ulcerative colitis and in maintenance therapy for prevention of relapses in ulcerative colitis . It is also useful in the ...
... therapeutic moiety is 5 - ASA . Sulfasalazine is a useful drug in the treatment of mild to moderate attacks of ulcerative colitis and in maintenance therapy for prevention of relapses in ulcerative colitis . It is also useful in the ...
Page 317
... therapeutic measures ( such as immunosup- presive therapy ) are added . For severe disease , as in ulcerative colitis , hospitalization is required and intravenous steroid therapy is begun with 60 mg methylprednisolone or its equivalent ...
... therapeutic measures ( such as immunosup- presive therapy ) are added . For severe disease , as in ulcerative colitis , hospitalization is required and intravenous steroid therapy is begun with 60 mg methylprednisolone or its equivalent ...
Contents
Approaches to Management | 3 |
Epidemiology | 23 |
Where Have We Been? Where Are We Going? | 29 |
Copyright | |
29 other sections not shown
Other editions - View all
Common terms and phrases
5-aminosalicylic acid abdominal abnormalities abscess acute anal anastomosis ankylosing spondylitis antibiotics antigens arthritis associated azathioprine barium biopsies cancer carcinoma cells chronic clinical colectomy colitis and Crohn's colon colonoscopy complications controlled trial corticosteroids Crohn's colitis Crohn's disease Crohn's disease patients diagnosis diarrhea diet dilatation disease activity disease and ulcerative distal dosage dose drug dysplasia endoscopic enemas epithelial evaluation factors fistulas Gastroenterology genetic hydrocortisone IBD patients ileal ileoanal ileostomy ileum immunosuppressive improved increased inflammation inflammatory bowel disease intestinal intravenous involvement Lancet lesions manifestations methotrexate metronidazole mucosa normal obstruction occur oral parenteral nutrition patients with Crohn's patients with ulcerative perianal physician placebo pouch procedure prednisolone prednisone present proctitis prognosis rectal rectum recurrence relapse remission reported resection response risk serum side effects sigmoidoscopic small bowel steroids stool strictures sulfasalazine surgery surgical symptoms therapeutic therapy tion tissue toxic megacolon treated Truelove ulcerative colitis usually